Retrospective analysis of type 2 diabetes prevalence in a systemic sclerosis cohort from southern Italy: Comment on “Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study” by Tseng et al., Joint Bone Spine 2016;83:307–13

Joint Bone Spine

Volumn 83, Issue 5, 2016, Pages 611-612

  Ursini, Francesco ^a,b   D'Angelo, Salvatore ^a   Padula, Angela ^a   Gilio, Michele ^a   Russo, Emilio ^b   Naty, Saverio ^b   De Sarro, Giovambattista ^b   Grembiale, Rosa Daniela ^b   Olivieri, Ignazio ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Body mass index; Glucose; Systemic sclerosis; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY; GLUCOSE; SCL 70 ANTIBODY; STEROID;

ADULT; AGED; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; ITALY; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; UNDERWEIGHT; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS;

COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; ITALY; PREVALENCE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84990876607     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.07.006     Document Type: Letter

References (10)

1. [1] Tseng, C.C., Chang, S.J., Tsai, W.C., et al. Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: a nationwide cohort study. Joint Bone Spine 83 (2016), 307–313.
2. [2] Ngian, G.S., Sahhar, J., Proudman, S.M., et al. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 71 (2012), 1980–1983.
3. [3] Nathan, D.M., Davidson, M.B., DeFronzo, R.A., et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30 (2007), 753–759.
4. [4] (IDF) IDF, IDF Diabetes Atlas. 7th edition, 2015.
5. [5] Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26 (2003), 61–69.
6. [6] Cowie, C.C., Rust, K.F., Byrd-Holt, D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care 29 (2006), 1263–1268.
7. [7] Lee, S.W., Kim, B.K., Park, J.Y., et al. Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. Clin Exp Rheumatol 33:Suppl 91 (2015), S68–S74.
8. [8] Changani, K.K., Jalan, R., Cox, I.J., et al. Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy. Gut 49 (2001), 557–564.
9. [9] Davies, C.A., Jeziorska, M., Freemont, A.J., et al. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37 (2006), 190–197.
10. [10] Takagi, H., King, G.L., Aiello, L.P., Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. Diabetes 47 (1998), 1480–1488.